125 related articles for article (PubMed ID: 38468522)
21. RANK and RANKL Expression in Salivary Gland Tumors.
Aslan F; Küçük Ü
Ear Nose Throat J; 2020 Aug; 99(7):475-480. PubMed ID: 32525717
[TBL] [Abstract][Full Text] [Related]
22. microRNA-143-3p regulates odontogenic differentiation of human dental pulp stem cells through regulation of the osteoprotegerin-RANK ligand pathway by targeting RANK.
Yang C; Jia R; Zuo Q; Zheng Y; Wu Q; Luo B; Lin P; Yin L
Exp Physiol; 2020 May; 105(5):876-885. PubMed ID: 32052500
[TBL] [Abstract][Full Text] [Related]
23. Receptor activator of nuclear factor κB expression is a prognostic factor in human osteosarcoma.
Trieb K; Windhager R
Oncol Lett; 2015 Sep; 10(3):1813-1815. PubMed ID: 26622756
[TBL] [Abstract][Full Text] [Related]
24. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
Hofbauer LC; Neubauer A; Heufelder AE
Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
[TBL] [Abstract][Full Text] [Related]
25. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B.
Mori K; Le Goff B; Berreur M; Riet A; Moreau A; Blanchard F; Chevalier C; Guisle-Marsollier I; Léger J; Guicheux J; Masson M; Gouin F; Rédini F; Heymann D
J Pathol; 2007 Apr; 211(5):555-562. PubMed ID: 17323424
[TBL] [Abstract][Full Text] [Related]
26. Impact of RANK signalling on survival and chemotherapy response in osteosarcoma.
Bago-Horvath Z; Schmid K; Rössler F; Nagy-Bojarszky K; Funovics P; Sulzbacher I
Pathology; 2014 Aug; 46(5):411-5. PubMed ID: 24842377
[TBL] [Abstract][Full Text] [Related]
27. Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization.
Jiang M; Peng L; Yang K; Wang T; Yan X; Jiang T; Xu J; Qi J; Zhou H; Qian N; Zhou Q; Chen B; Xu X; Deng L; Yang C
J Med Chem; 2019 Jun; 62(11):5370-5381. PubMed ID: 31082234
[TBL] [Abstract][Full Text] [Related]
28. RANKL blockade prevents and treats aggressive osteosarcomas.
Chen Y; Di Grappa MA; Molyneux SD; McKee TD; Waterhouse P; Penninger JM; Khokha R
Sci Transl Med; 2015 Dec; 7(317):317ra197. PubMed ID: 26659571
[TBL] [Abstract][Full Text] [Related]
29. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models.
Rousseau J; Escriou V; Lamoureux F; Brion R; Chesneau J; Battaglia S; Amiaud J; Scherman D; Heymann D; Rédini F; Trichet V
J Bone Miner Res; 2011 Oct; 26(10):2452-62. PubMed ID: 21713988
[TBL] [Abstract][Full Text] [Related]
30. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of periostin, sclerostin, receptor activator of nuclear factor-κB, and receptor activator of nuclear factor-κB ligand genes in severe chronic periodontitis.
Sankardas PA; Lavu V; Lakakula BVKS; Rao SR
J Investig Clin Dent; 2019 Feb; 10(1):e12369. PubMed ID: 30375186
[TBL] [Abstract][Full Text] [Related]
32. An in vitro and in silico investigation of human pregnane X receptor agonistic activity of poly- and perfluorinated compounds using the heuristic method-best subset and comparative similarity indices analysis.
Zhang YM; Wang T; Yang XS
Chemosphere; 2020 Feb; 240():124789. PubMed ID: 31561157
[TBL] [Abstract][Full Text] [Related]
33. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
34. Receptor activator of nuclear factor-κB ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice.
Sakai N; Van Sweringen HL; Schuster R; Blanchard J; Burns JM; Tevar AD; Edwards MJ; Lentsch AB
Hepatology; 2012 Mar; 55(3):888-97. PubMed ID: 22031462
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
[TBL] [Abstract][Full Text] [Related]
36. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
37. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.
Wittrant Y; Lamoureux F; Mori K; Riet A; Kamijo A; Heymann D; Redini F
Int J Oncol; 2006 Jan; 28(1):261-9. PubMed ID: 16328004
[TBL] [Abstract][Full Text] [Related]
38. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
Golden D; Saria EA; Hansen MF
J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
[TBL] [Abstract][Full Text] [Related]
39. Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
Mori K; Ando K; Heymann D; Rédini F
Histol Histopathol; 2009 Feb; 24(2):235-42. PubMed ID: 19085839
[TBL] [Abstract][Full Text] [Related]
40. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
